Treatment of Chronic Dandruff (Seborrheic Dermatitis)

Understanding the Condition

Step-by-Step Treatment Approach

Step 1 - Mild Dandruff (OTC First Line)

Step 2 - Moderate to Severe Disease (Prescription)

• Ketoconazole 2% shampoo - Twice weekly for 4 weeks (acute), then once every 1-2 weeks for maintenance. NICE CKS, Nov 2024
• Ciclopirox 1% shampoo - Effective alternative; twice weekly during flares

• Betamethasone valerate 0.1% scalp application - Morning and evening for 5 days only
• Mometasone furoate 0.1% scalp lotion - Once daily, short course
• Hydrocortisone 1% cream - For mild inflammation, up to 2 weeks

Avoid long-term regular corticosteroid use on the scalp/face - it causes irreversible skin thinning and striae formation. - Tintinalli's Emergency Medicine, p. 1696

Step 3 - Resistant or Recurrent Cases

• Tacrolimus 0.1% (Protopic) or Pimecrolimus 1% (Elidel)
• Reduce inflammation without skin-thinning risk - preferred for long-term facial use
• Used once or twice daily acutely, then once weekly for maintenance
• Note: FDA theoretical cancer risk warning - avoid continuous indefinite use

• Itraconazole 200 mg/day or Fluconazole 200 mg/day for 5-7 days
• Reserved for very severe or widespread involvement
• Harrison's, p. 1767

• Roflumilast foam 0.3% (PDE4 inhibitor) - A 2024 Phase 3 RCT in JAAD showed significant efficacy for seborrheic dermatitis. This is a newer option for refractory cases.

Maintenance Therapy (Critical for Chronic Cases)

• After clearing a flare, continue medicated shampoo once every 1-2 weeks indefinitely
• Ketoconazole 2% once weekly is the most common maintenance regimen
• Some patients do well alternating an antifungal shampoo with a coal tar or zinc pyrithione shampoo

Lifestyle and Adjunct Measures

• Stress management - stress does not cause dandruff but is a recognized trigger for flares
• Limit harsh styling products - gels and sprays can worsen scale buildup
• Regular shampooing - daily shampooing with a gentle shampoo between medicated shampoo use reduces yeast load
• Avoid scratching - worsens inflammation and can introduce secondary bacterial infection
• Diet: A 2024 systematic review (PMID 39102684) found associations between obesity/diet and seborrheic dermatitis severity; a balanced diet may help

When to See a Dermatologist

• No response after 8-12 weeks of first- and second-line treatment
• Severe, widespread, or rapidly spreading disease
• Associated with HIV/AIDS (seborrheic dermatitis can be severe and treatment-resistant in immunocompromised patients)
• Associated with Parkinson's disease (autonomic dysfunction increases sebum production)
• Uncertain diagnosis - rule out scalp psoriasis, tinea capitis, or contact dermatitis

Summary Table

Treatment of Neuroleptic Malignant Syndrome (NMS)

What is NMS?

1. Altered mental status (confusion, stupor, agitation - usually the first sign)
2. Lead-pipe muscle rigidity (severe, generalized)
3. Hyperthermia (fever >38°C)
4. Autonomic instability (BP fluctuations, diaphoresis, tachycardia, urinary incontinence)

Immediate Management (Emergency)

Step 1 - STOP the Offending Drug (Most Important)

• Discontinue ALL antipsychotics and dopamine-blocking agents immediately - this includes typical antipsychotics (haloperidol, chlorpromazine), atypical antipsychotics (olanzapine, risperidone, clozapine, aripiprazole), and antiemetic dopamine antagonists (metoclopramide, prochlorperazine)
• Also stop any potentiating drugs: anticholinergics, antihistamines, lithium
• Symptoms typically resolve within 1-2 weeks after stopping; depot injections may prolong course up to 1 month
• Do NOT mistake NMS for worsening psychosis and give more antipsychotic - this is the most dangerous error. - Adams & Victor's, p. 1210

Step 2 - ICU Admission

Supportive Care (Core of Treatment)

Temperature Control

• External cooling: evaporative cooling (mist bare skin + fan), ice packs, cooled saline IV
• Target: reduce core temperature to <39°C within 30 minutes
• Pharmacologic antipyretics (e.g., paracetamol) are not effective for NMS-associated hyperthermia - the fever is muscle-generated, not hypothalamic - Tintinalli's, p. 1253
• Acetaminophen 1000 mg every 6 hours is sometimes added, but cooling is primary (NEJM 2024 review, PMID 39321364)

Airway and Breathing

• Anticipate airway compromise due to hypersalivation, dysphagia, decreased reflexes
• Early intubation strongly recommended if hypersalivation, fever + rigidity, acidosis, or hypoxia present
• Use non-depolarizing agents (rocuronium, vecuronium) for intubation - depolarizing agents (succinylcholine) are contraindicated in rhabdomyolysis due to risk of fatal hyperkalemia - Tintinalli's, p. 1253

IV Fluids and Rhabdomyolysis

• Aggressive IV hydration to maintain urine output ~200-300 mL/hour
• Urinary alkalinization with IV sodium bicarbonate to prevent myoglobin-induced acute kidney injury
• Mannitol may be considered for severe rhabdomyolysis
• Monitor creatine kinase (often >1000 IU/mL, sometimes up to 60,000 IU/mL), renal function, electrolytes, and myoglobinuria
• Dialysis if severe hyperkalemia, hypocalcemia, azotemia, or volume overload

VTE Prophylaxis

• Low-molecular-weight heparin should be started early - venous thromboembolism is a major cause of morbidity and mortality in NMS - Rosen's Emergency Medicine, p. 3017

Hemodynamic Management

• Treat dysautonomia: clonidine for hypertension, clevidipine for hypertensive crises
• Continuous cardiac monitoring (QTc)

Pharmacologic Treatment

1. Benzodiazepines (First-Line for Agitation and Rigidity)

• Lorazepam 1-2 mg IV every 2-4 hours as needed (Tintinalli's); some sources use 1-2 mg IV every 5-10 min until rigidity improves (Rosen's)
• Reduces agitation, sympathetic overactivity, and muscle tension
• Preferred as initial pharmacotherapy in the ED and ICU
• Propofol is an alternative for intubated patients

2. Dantrolene (For Severe/Refractory Rigidity)

• Reduces mean recovery time to ~9 days vs. 15 days with supportive care alone (NEJM 2024 review)

3. Bromocriptine (Dopamine Agonist)

• Early administration (when consciousness is first altered and temperature just rising) can terminate the condition within a few hours. - Adams & Victor's, p. 1210

4. Amantadine (Dopamine Agonist - Alternative)

• 100 mg PO three times daily
• Oral dopamine agonist; similar mechanism to bromocriptine
• Fewer side effects; useful when bromocriptine is unavailable
• Equally effective per case series

5. Electroconvulsive Therapy (ECT) - Refractory Cases

• Reserved for NMS refractory to all pharmacologic treatment
• Particularly valuable because NMS may be indistinguishable from malignant catatonia (for which ECT is first-line)
• An advantage: ECT can continue when antipsychotics must be withheld
• Evidence is limited to case series, but can be lifesaving
• Recent 2025 reports confirm ECT success even in refractory NMS with coexisting catatonia (Cambridge Medicine, 2025)

Diagnostic Criteria (Tintinalli's Table 180-2)

• Fever >38°C on ≥2 occasions
• Lead-pipe muscle rigidity
• Psychomotor slowing / altered mental status
• Autonomic instability (≥2 of: elevated BP, BP fluctuation, diaphoresis, urinary incontinence)
• Recent dopamine antagonist exposure or agonist withdrawal

NMS vs. Serotonin Syndrome (Key Differential)

• Tintinalli's, p. 1253

Summary Algorithm

Suspect NMS (tetrad: AMS + rigidity + fever + autonomic instability)
        ↓
STOP all antipsychotics + dopamine antagonists
        ↓
ICU admission + airway assessment
        ↓
External cooling + aggressive IV hydration + VTE prophylaxis
        ↓
Lorazepam 1-2 mg IV q2-4h (agitation + rigidity)
        ↓
If temp ≥38-40°C + moderate-severe rigidity:
  → Add Bromocriptine 2.5 mg PO TID (dopamine agonist)
  → Add Dantrolene 1-2.5 mg/kg IV load (muscle relaxant)
        ↓
Refractory → ECT

Restarting Antipsychotics After NMS

• Wait at least 2 weeks after full resolution before considering rechallenge
• If antipsychotic is essential, choose a lower-potency atypical (e.g., quetiapine) - SGAs have lower NMS risk
• Start at low doses, titrate slowly
• Risk of recurrence on rechallenge is real but lower than commonly feared - Rosen's, p. 3017